Experimental drug cilengitide tested with Chemo-Radiation for lung cancer
NCT ID NCT01118676
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested the drug cilengitide given continuously along with standard chemotherapy and radiation in 14 patients with locally advanced non-small cell lung cancer. The main goal was to find the highest safe dose of cilengitide when used this way. Researchers also looked at how well the tumors responded and how long patients lived.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cilengitide
- What this could lead to
- If successful, this could help determine a safe dose of cilengitide combined with standard chemoradiation for advanced lung cancer.
- What could go wrong
- This is a very early, small Phase 1 trial with only 14 patients, so it cannot prove effectiveness. The main goal is safety, not treatment benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Toulouse Larrey
Toulouse, 31000, France
-
Institut Claudius Regaud
Toulouse, 31000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.